Corbus (CRBP) Moves Down in Pre-Market Trading for June 22

Equities Staff  |

Shares of Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) are on the move in pre-market trading for June 22.

Ahead of the market's open, Corbus stock fell 6.05% from the previous session’s close.

Corbus was down $0.0128 in the last session and looks to be in play again today.

For technical charts, analysis, and more on Corbus visit the company profile.

Pre-market prices and movements as of 07:51:58 est.

About Corbus Pharmaceuticals Holdings Inc

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. The Company's lead product candidate, lenabasum, is a novel, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to provide an alternative to immunosuppressive medications in the treatment of chronic inflammatory and fibrotic diseases. Lenabasum is currently being evaluated in dermatomyositis and systemic lupus erythematosus. Corbus is also developing a pipeline of other preclinical drug candidates from its endocannabinoid system platform.

To get more information on Corbus Pharmaceuticals Holdings Inc and to follow the company's latest updates, you can visit the company's profile page here: Corbus Pharmaceuticals Holdings Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Best Laid Plans of Mice and Men — Part II
Why I’m Buying the 'New' Value Stocks
Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade



Market Movers

Sponsored Financial Content